Literature DB >> 15703383

Cephalostatin 1 inactivates Bcl-2 by hyperphosphorylation independent of M-phase arrest and DNA damage.

Irina M Müller1, Verena M Dirsch, Anita Rudy, Nancy López-Antón, George R Pettit, Angelika M Vollmar.   

Abstract

Cephalostatin 1 is a marine product that induces a novel cytochrome c-independent apoptotic pathway in Jurkat leukemia T cells (Cancer Res 63:8869-8876, 2003). Here, we show that overexpression of the antiapoptotic protein Bcl-2 protects cells only partially against cephalostatin 1-induced apoptosis. The mechanism of Bcl-2 inactivation by cephalostatin 1 is based on hyperphosphorylation of Bcl-2 on Thr69 and Ser87 because Jurkat cells overexpressing a Bcl-2 protein with mutations on both phosphorylation sites were completely protected against cephalostatin 1. In search of the kinase responsible for Bcl-2 phosphorylation, c-Jun NH2-terminal kinase (JNK) was found to be activated by cephalostatin 1. Reduction of Bcl-2 phosphorylation by the specific JNK inhibitor (anthra(1,3-cd)pyrazol-6(2H)-one) SP600125 suggested a crucial role for JNK in this process. JNK activation was not a consequence of DNA damage, a known stimulus of JNK, because cephalostatin 1 did not induce DNA lesions as shown by the comet assay. Arrest in M-phase is also demonstrated to be associated with JNK activation. However, cephalostatin 1 does not evoke an arrest in M-phase as shown by flow cytometry. Together, cephalostatin 1 is shown to induce JNK activation with subsequent Bcl-2 phosphorylation and inactivation. Reported triggers, such as the induction of an M-phase arrest or DNA damage are not involved in this process, suggesting a novel mechanism for cephalostatin 1-mediated Bcl-2 hyperphosphorylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15703383     DOI: 10.1124/mol.104.004234

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

Review 1.  Chemistry of trisdecacyclic pyrazine antineoplastics: the cephalostatins and ritterazines.

Authors:  Seongmin Lee; Thomas G LaCour; Philip L Fuchs
Journal:  Chem Rev       Date:  2009-06       Impact factor: 60.622

2.  Ritterostatin GN 1N , a Cephalostatin-Ritterazine Bis-steroidal Pyrazine Hybrid, Selectively Targets GRP78.

Authors:  Andrew J Ambrose; Evelyne A Santos; Paula C Jimenez; Danilo D Rocha; Diego V Wilke; Paolo Beuzer; Josh Axelrod; Ananda Kumar Kanduluru; Philip L Fuchs; Hu Cang; Letícia V Costa-Lotufo; Eli Chapman; James J La Clair
Journal:  Chembiochem       Date:  2017-02-02       Impact factor: 3.164

3.  The cephalostatins. 22. synthesis of bis-steroidal pyrazine pyrones (1).

Authors:  George R Pettit; Bryan R Moser; Ricardo F Mendonça; John C Knight; Fiona Hogan
Journal:  J Nat Prod       Date:  2012-05-18       Impact factor: 4.050

4.  Functional evaluation of a fluorescent schweinfurthin: mechanism of cytotoxicity and intracellular quantification.

Authors:  Craig H Kuder; Ryan M Sheehy; Jeffrey D Neighbors; David F Wiemer; Raymond J Hohl
Journal:  Mol Pharmacol       Date:  2012-03-29       Impact factor: 4.436

Review 5.  Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds.

Authors:  Alejandro M S Mayer; Kirk R Gustafson
Journal:  Eur J Cancer       Date:  2008-08-11       Impact factor: 9.162

6.  Oxysterol-binding protein (OSBP)-related protein 4 (ORP4) is essential for cell proliferation and survival.

Authors:  Mark Charman; Terry R Colbourne; Antonietta Pietrangelo; Laurent Kreplak; Neale D Ridgway
Journal:  J Biol Chem       Date:  2014-04-16       Impact factor: 5.157

7.  Computationally guided organometallic chemistry: preparation of the heptacyclic pyrazine core of ritterazine N.

Authors:  Douglass F Taber; Karen V Taluskie
Journal:  J Org Chem       Date:  2006-03-31       Impact factor: 4.354

Review 8.  Asymmetric synthesis of naturally occurring spiroketals.

Authors:  B Rama Raju; Anil K Saikia
Journal:  Molecules       Date:  2008-08-28       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.